Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $84.58 Average PT from Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have been given an average rating of “Moderate Buy” by the thirteen research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $84.5833.

Several analysts have recently commented on VERA shares. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Evercore set a $91.00 price objective on Vera Therapeutics in a research report on Friday, May 15th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Guggenheim increased their target price on Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Friday, July 17th.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the sale, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 83,250 shares of company stock worth $3,337,770. Company insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after buying an additional 236 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Vera Therapeutics in the 4th quarter worth approximately $46,000. Aster Capital Management DIFC Ltd acquired a new position in Vera Therapeutics in the 4th quarter valued at $71,000. Quantbot Technologies LP acquired a new position in Vera Therapeutics in the 2nd quarter valued at $51,000. Finally, Sandia Investment Management LP purchased a new position in shares of Vera Therapeutics during the 4th quarter worth $127,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 2.4%

Shares of NASDAQ VERA opened at $32.51 on Friday. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -5.87 and a beta of 0.92. Vera Therapeutics has a 52 week low of $19.07 and a 52 week high of $56.05. The firm has a 50-day moving average price of $36.97 and a 200 day moving average price of $39.79. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the business posted ($0.81) EPS. Equities research analysts anticipate that Vera Therapeutics will post -6.37 EPS for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.